{"entity":{"id":"isotypes-and-fc-silencing","kind":"term","name":"Antibody isotypes and Fc silencing","aka":["antibody isotype","isotype","IgG subclass","Fc silencing","class switching"],"tldr":"An antibody's class and the design of its stem change how it connects to immune cells and complement. Switching off one connection does not switch off all of them, and does not make the finished drug harmless.","summary":"An isotype is a heavy-chain class: IgM, IgD, IgG, IgA or IgE, and human IgG also has the subclasses IgG1, IgG2, IgG3 and IgG4. The classes differ in architecture, distribution and potential effector interactions. Vidarsson et al. (2014) review how the four IgG subclasses differ in their hinges and upper CH2 domains, which bind Fc gamma receptors and C1q, giving different effector functions, while the Fc also carries a binding site for the neonatal Fc receptor (FcRn) that extends half-life. A B-cell lineage can undergo class switching, changing the constant region while keeping the rearranged variable-region sequence; this differs from the mutations that change affinity during a response, and neither the class nor a switch says what antigen an antibody recognises. Subclass, Fc sugars, target geometry and the available cells all affect interactions, so IgG1 and IgG4 are not interchangeable but neither name fully predicts behaviour. As a real example, pembrolizumab is a humanised IgG4 kappa antibody (FDA label, section 11); its intended job is to block the PD-1 receptor, not to recruit killer cells to the T cells it binds.\n\nFc silencing uses design changes to reduce selected receptor or complement interactions. Lo et al. (2017) found that the commonly used N297G and D265A/N297G variants, effective at attenuating effector function in primates, retained potent complement activation in mice and created safety liabilities in murine studies, whereas an L234A, L235A, P329G (LALA-PG) variant eliminated complement binding and attenuated effector activity in that setting. That supports engineering a particular interaction in a particular species; it does not prove universal human safety or silence in every assay. IgG4 is not a synonym for a fully silent Fc.\n\nFcRn has a separate role in IgG transport and recycling, so reduced Fc gamma receptor recruitment does not by itself establish reduced FcRn binding or a shorter half-life. Compare matched molecules with the same binding regions and measure target binding, Fc gamma receptor and C1q binding, and killing, engulfment or complement damage separately, stating species, receptor variants, concentrations and effector cells; FcRn binding and exposure are further questions. An antibody meant to remove a target-bearing cell may benefit from effector recruitment, whereas one meant to block an immune receptor may need to avoid removing useful receptor-bearing cells, but Fc attenuation alone does not establish loss of target binding or absence of payload toxicity or inflammation.","asOf":"2026-11-09","links":[{"label":"Vidarsson et al., 2014, Frontiers in Immunology (PMID 25368619)","url":"https://doi.org/10.3389/fimmu.2014.00520"},{"label":"Lo et al., 2017, Journal of Biological Chemistry (PMID 28077575)","url":"https://doi.org/10.1074/jbc.M116.767749"},{"label":"FDA label for pembrolizumab, section 11 (IgG4 kappa)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s194lbl.pdf"},{"label":"Nimmerjahn and Ravetch, 2005, Science (PMID 16322460)","url":"https://doi.org/10.1126/science.1118948"},{"label":"OpenStax Microbiology 18.4: B-cell recognition and class switching (educational source)","url":"https://openstax.org/books/microbiology/pages/18-4-b-lymphocytes-and-humoral-immunity"}],"tags":["education-immunology-2026-11"],"related":["fc-effector","antibody","adcc-adcp-cdc","half-life","pembrolizumab","antibody-structure"],"cancers":[],"sections":[],"technologies":[],"targets":["fcgr3a","fcgr2a","fcgr2b"],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["fc-effector","antibody","half-life","antibody-structure","adcc-adcp-cdc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Label read from the FDA PDF on 9 November 2026 (humanized monoclonal IgG4 kappa antibody, about 149 kDa). Lo 2017 and Vidarsson 2014 read at abstract depth.","The class switching versus affinity maturation distinction is taught from Janeway's Immunobiology (not opened here: scripted access refused).","Additional source check: the Structure and Fc-interaction sections of the accessible Vidarsson 2014 review were read directly. They describe two heavy and two light chains, variable and constant domains, Fab/Fc and hinge anatomy, subclass differences and FcRn interactions. This is review evidence, separate from the mouse and biochemical primary experiments.","Additional educational source: the B-cell receptor and class-switching passages of OpenStax Microbiology 18.4 were read in raw page text. Class switching changes the constant-region class while retaining the rearranged variable-region sequence; it differs from affinity-changing mutation. This is textbook evidence, separate from the cited primary experiments."],"category":"Immunology"},"route":"/terms/isotypes-and-fc-silencing/","neighbours":{"term":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"antibody-structure","kind":"term","name":"Antibody structure (Fab, Fc and hinge)","route":"/terms/antibody-structure/"},{"id":"adcc-adcp-cdc","kind":"term","name":"Antibody-guided effector mechanisms (ADCC, ADCP, CDC)","route":"/terms/adcc-adcp-cdc/"},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/"},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"target":[{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/"},{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/"},{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/"}]}}